Inventor · disambiguated record
David Fabrizio
Also filed as: FABRIZIO DAVID · FABRIZIO DAVID A
23 granted patents·12 pending applications·273 citations·filing 2007–2025
96Inventor score
Files withBRISTOL MYERS SQUIBB CO19GENENTECH INC8FOUND MEDICINE INC5CAMPHAUSEN RAY2GOSSELIN MICHAEL L1
Top patents by PatentIndex Score
35 records- 0196US9920108B2Targeted therapeutics based on engineered proteins that bind EGFRBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Mar 20, 2018·19 cites·14 claims
- 0296US8524244B2Targeted therapeutics based on engineered proteins that bind EGFRCAMPHAUSEN RAY·Filed 2009·Granted Sep 3, 2013·44 cites·24 claims
- 0396US8470332B2Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IRCAMPHAUSEN RAY·Filed 2007·Granted Jun 25, 2013·41 cites·13 claims
- 0495US10406251B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 10, 2019·15 cites·35 claims
- 0595US9234028B2Targeted therapeutics based on engineered proteins that bind EGFRBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 12, 2016·30 cites·19 claims
- 0694US9540424B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 10, 2017·27 cites·19 claims
- 0794US8969289B2Serum albumin binding moleculesGOSSELIN MICHAEL L·Filed 2011·Granted Mar 3, 2015·45 cites·33 claims
- 0893US10221438B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 5, 2019·12 cites·16 claims
- 0991US11279767B2Therapeutic and diagnostic methods for cancerGENENTECH INC·Filed 2018·Granted Mar 22, 2022·7 cites·11 claims
- 1091US11173219B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 16, 2021·4 cites·21 claims
- 1191US10934572B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 2, 2021·4 cites·16 claims
- 1290US11300570B2Therapeutic and diagnostic methods for cancerGENENTECH INC·Filed 2019·Granted Apr 12, 2022·3 cites·18 claims
- 1390US10442851B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 15, 2019·5 cites·12 claims
- 1490US10221232B2Methods of treating cancer by administering IGF-IR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 5, 2019·7 cites·10 claims
- 1589US11344639B2PET imaging with PD-L1 binding polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted May 31, 2022·4 cites·13 claims
- 1689US10781247B2Targeted therapeutics based on engineered proteins that bind EGFRBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Sep 22, 2020·3 cites·17 claims
- 1786US11203630B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 21, 2021·2 cites·9 claims
- 1882US11149077B2Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IRBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 19, 2021·1 cites·10 claims
- 1981US2025244329A1Therapeutic and diagnostic methods for cancerGENENTECH INC·Filed 2024·Application pending·0 cites
- 2078US2024288430A1Therapeutic and diagnostic methods for cancerGENENTECH INC·Filed 2023·Application pending·0 cites
- 2176US2025306027A1Therapeutic and diagnostic methods for cancerGENENTECH INC·Filed 2025·Application pending·0 cites
- 2274US12194110B2PD-L1 binding polypeptides for imagingBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jan 14, 2025·0 cites·15 claims
- 2374US2022412981A1Therapeutic and diagnostic methods for cancerGENENTECH INC·Filed 2022·Application pending·0 cites
- 2471US12331128B2Therapeutic and diagnostic methods for cancerGENENTECH INC·Filed 2022·Granted Jun 17, 2025·0 cites·13 claims
- 2571US2021040181A1Targeted therapeutics based on engineered proteins that bind egfrBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2667US2013310317A1Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-irBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 2766US2022347324A1Pet imaging with pd-l1 binding polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2865US11674962B2Therapeutic and diagnostic methods for cancerGENENTECH INC·Filed 2018·Granted Jun 13, 2023·0 cites·16 claims
- 2964US2024392378A1Methods of treating cancerFOUND MEDICINE INC·Filed 2023·Application pending·0 cites
- 3063US2025210194A1Methods and systems for determining tumor heterogeneityFOUND MEDICINE INC·Filed 2023·Application pending·0 cites
- 3161US2015252097A1Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-irBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 3259US12473589B2Compositions and methods for evaluating genomic alterationsFOUND MEDICINE INC·Filed 2025·Granted Nov 18, 2025·0 cites·18 claims
- 3353US11725247B2Methods of treating cancerFOUND MEDICINE INC·Filed 2017·Granted Aug 15, 2023·0 cites·16 claims
- 3449US2014256589A1Methods for accelerated selection of polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 3546US2018363066A1Methods and systems for evaluating tumor mutational burdenFOUND MEDICINE INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Fabrizio files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →